The present invention relates to compositions comprising molecular iodine and a vehicle comprising a semifluorinated alkane. The compositions of the invention may be used to treat or prevent diseases or conditions caused by, or associated with microorganisms.

The present invention relates to compositions comprising molecular iodine and a vehicle comprising a semifluorinated alkane. The compositions of the invention may be used to treat or prevent diseases or conditions caused by, or associated with microorganisms.

The present disclosure is in the field of ointments which can be useful for the treatment of diseases or conditions associated with lipid barrier damage of the skin. The ointment comprises a semifluorinated alkane and a solid thickening agent, e.g., a wax, a triglyceride, cetyl alcohol, cetyl palmitate, or tetradecanol.

The present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.

The present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.

The disclosure relates to methods for treating cutaneous aging by administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor.

The present invention provides a cosmetic composition including oxygen-containing microspheres for preventing skin aging, in which the microsphere contains 25 to 35 ppm of oxygen. The cosmetic composition including the microsphere according to the present invention is capable of supplying a high concentration of oxygen to the skin by allowing a high concentration of oxygen to slowly release through the microspheres.

The present disclosure relates to topical sunscreen formulations comprising a semifluorinated alkane and a metal oxide selected from titanium dioxide, zinc oxide or mixtures thereof.

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I):

##STR00001## wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably tram); or —CR.sub.a═CR.sub.b— a stilbene derivative; where R.sub.a and R.sub.b are independently H or phenyl optionally substituted with —(R.sup.3).sub.p or —(R.sup.4).sub.q; R.sup.1 to R.sup.4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≥1. Each R.sup.1 to R.sup.2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I):

##STR00001## wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably tram); or —CR.sub.a═CR.sub.b— a stilbene derivative; where R.sub.a and R.sub.b are independently H or phenyl optionally substituted with —(R.sup.3).sub.p or —(R.sup.4).sub.q; R.sup.1 to R.sup.4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≥1. Each R.sup.1 to R.sup.2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.